The Free Radical Cancer Biology Program (FRCBP) is unique to the HCCC and focuses on studying the biology of inherent differences in reductive and oxidative (redox) metabolism between cancer vs. normal cells. Research in the program is determining the role that redox reactions play in cancer phenotypic changes relevant to cell growth, differentiation, signal transduction, metastasis, functional molecular imaging, and therapy. A unifying goal of the program is to utilize a comprehensive basic science understanding of redox biology to develop novel biochemical rationales for improving cancer therapy. Three overlapping themes exist within the program. Theme 1: Understanding the role of redox biochemistry in regulation of genetic and epigenetic gene expression pathways relevant to cancer biology. Within this theme are research areas of focus exploring redox fluctuations and gene expression globally, as well as gene expression changes related of key redox sensitive molecules such as glutathione, thioredoxin, SOD, and AP2. Ttieme 2: Understanding the role of redox regulation in cell biology. Within this theme are research areas exploring the effects of redox on the cell cycle as well as invasion and metastasis. Ttieme 3: Exploring the role of oxidative stress in therapy outcomes. Within this theme are research areas exploring the role of manipulating oxidative stress to improve therapy as well as using imaging of oxidative metabolism as an approach to monitor and guide therapy. Major accomplishments of the FRCBP over the past funding period include findings that (a) cancer cells (relative to normal cells) produce increased steady-state levels of 02*'and H2O2 from mitochondrial metabolism that significantly contribute to differential susceptibility to clonogenic cell killing induced by glucose deprivation;(b) extracellular superoxide dismutase (EcSOD) inhibits invasion and metastasis;(c) expression of MnSOD governs the late production of reactive oxygen species, cell cycle check points, and transformation following radiation exposure;(d) that inhibitors of glucose and hydroperoxide metabolism can be used to enhance responses to radio-chemo-therapy by enhancing metabolic oxidative stress. The FRCBP consists of 18 members from 1 basic science department and 6 clinical departments and 2 colleges. Peer-reviewed, research funding for this program totals $3.9 million with over $2.0 million total costs from NCI. FRCBP members co-authored 237 publications. Of these publications, 20% were intraprogrammatic, 24% were interprogrammatic and 10% were both intra and interprogrammatic, for a total of 54% collaborative publications.

Public Health Relevance

It is becoming clear that metabolic oxidation/reduction reactions are altered in cancer vs. normal cells. The consensus is that cancer cells may exist in a chronic state of metabolic oxidative stress that may represent a significant underlying mechanism contributing to malignancy. A unifying goal of research in the FRCBP is to utilize a comprehensive understanding of cancer vs. normal cell redox biology to develop novel biochemical rationales for improving cancer therapy taking advantage fundamental differences in oxidative metabolism.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-12
Application #
8381307
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-05-03
Budget End
2013-03-31
Support Year
12
Fiscal Year
2012
Total Cost
$44,646
Indirect Cost
$32,873
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Kim, Yusung; Cabel, Katherine; Sun, Wenqing (2018) Does the apex optimization line matter for single-channel vaginal cylinder brachytherapy planning? J Appl Clin Med Phys 19:307-312
Hagan, Teresa L; Gilbertson-White, Stephanie; Cohen, Susan M et al. (2018) Symptom Burden and Self-Advocacy: Exploring the Relationship Among Female Cancer Survivors?. Clin J Oncol Nurs 22:E23-E30
Chesney, Jason; Puzanov, Igor; Collichio, Frances et al. (2018) Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol 36:1658-1667
Brooks, Jennifer D; Comen, Elizabeth A; Reiner, Anne S et al. (2018) CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study. Breast Cancer Res 20:149
Chioreso, Catherine; Del Vecchio, Natalie; Schweizer, Marin L et al. (2018) Association Between Hospital and Surgeon Volume and Rectal Cancer Surgery Outcomes in Patients With Rectal Cancer Treated Since 2000: Systematic Literature Review and Meta-analysis. Dis Colon Rectum 61:1320-1332
Musselman, Catherine A; Kutateladze, Tatiana G (2018) A histone reader becomes the readout. J Biol Chem 293:7486-7487
Merritt, Nicole M; Fullenkamp, Colleen A; Hall, Sarah L et al. (2018) A comprehensive evaluation of Hippo pathway silencing in sarcomas. Oncotarget 9:31620-31636
Haskins, Cole B; McDowell, Bradley D; Carnahan, Ryan M et al. (2018) Impact of preexisting mental illness on breast cancer endocrine therapy adherence. Breast Cancer Res Treat :
Daneshmand, Siamak; Patel, Sanjay; Lotan, Yair et al. (2018) Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. J Urol 199:1158-1165
Borcherding, Nicholas; Kolb, Ryan; Gullicksrud, Jodi et al. (2018) Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. J Mol Biol 430:2014-2029

Showing the most recent 10 out of 1080 publications